Related Experiment Video

Updated: Apr 11, 2026

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

1.8K

Propranolol in the Treatment of Infantile Hemangiomas: A Meta-Analysis in Chinese Patients

Lin-Lin Li1, Lu Yan1, Miao-Xuan Luo1

  • 1ZhuJiang Hospital, Southern Medical University, Guangzhou, China.

Pediatric Dermatology
|June 11, 2015
PubMed

Insights

Propranolol is effective for treating infantile hemangiomas (IHs) in Chinese infants, showing a significant difference compared to corticosteroids. This meta-analysis confirms propranolol

Area of Science:

  • Pediatric dermatology
  • Pharmacology
  • Medical research

Background:

  • Infantile hemangiomas (IHs) are common vascular tumors in infants.
  • Corticosteroids have been a traditional treatment for IHs.
  • Emerging evidence suggests propranolol as a potential therapeutic agent.

Purpose of the Study:

  • To evaluate the efficacy of propranolol in treating infantile hemangiomas (IHs) specifically in Chinese infants.
  • To compare the effectiveness of propranolol with corticosteroids for IH treatment.
  • To synthesize pooled data from multiple studies on propranolol for IHs.

Main Methods:

  • A meta-analysis was performed on data from 26 single-arm studies.
  • Studies focused on the use of propranolol for infantile hemangiomas in Chinese infants.
  • Statistical analysis was conducted to determine the overall treatment effect and compare with corticosteroids.

Main Results:

  • A statistically significant difference in efficacy was observed between propranolol and corticosteroid treatments (p < 0.001).
  • The pooled overall effect of propranolol for infantile hemangiomas in Chinese infants was 93% (95% CI: 0.88, 0.96).
  • This indicates a high success rate for propranolol in this population.

Conclusions:

  • Propranolol demonstrates significant efficacy in the treatment of infantile hemangiomas in Chinese infants.
  • Propranolol is a superior treatment option compared to corticosteroids for IHs in this demographic.
  • The findings support the use of propranolol as a first-line therapy for infantile hemangiomas in Chinese infants.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
615
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
567